TKPHF News and Press, Takeda Pharmaceutical Co Ltd From 08/19/20

This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 08/14/2020. Please visit our Tracking John Paulson's Paulson & Company Portfolio serie...

Biogen receives priority review for Alzheimer’s drug candidate Biogen ( BIIB ) announced that the FDA has accepted its Biologics License Application for aducanumab. The application has been granted Priority Review and its PDUFA date has been set at March 7, 2021. The agency has ...

Quick Take Freeline Therapeutics Holdings plc ( FRLN ) intends to raise $125 million from the sale of ADSs representing underlying common stock in an IPO, according to an amended registration statement . The company is advancing a pipeline of treatment candidates for hemophilia, Gaucher d...

Takeda Pharmaceutical Co Ltd (TAK) Q1 2021 Earnings Conference Call July 31, 2020, 05:30 ET Company Participants Takashi Okubo - Global Head, IR, Global Finance Christophe Weber - President, CEO & Representative Director Andrew Plump - President, Research & Development &a...

Quick Take AlloVir ( ALVR ) intends to raise $251 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is a mid stage firm developing drug treatments for virus conditions. ALVR is preparing to enter Phase 3 trials and has an e...

Quick Take Freeline Therapeutics Holdings plc ( FRLN ) has filed to raise $100 million in an IPO of its ADSs representing underlying ordinary shares, according to an F-1 registration statement . The company is a gene therapy biopharma developing treatments for hemophilia B and other serio...

Quick Take Annexon ( ANNX ) intends to raise $150 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatments for autoimmune and neurodegenerative conditions. ANNX is pursuing multiple treatment programs with...

Quick Take AlloVir ( ALVR ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The company is a mid-stage clinical biopharma firm developing treatments for various virus infections. ALVR is seeking funding to advance its lead cand...

Quick Take Annexon ( ANNX ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is a clinical stage biopharma developing antibodies for treating autoimmune and neurodegenerative diseases. ANNX is targeting a number of s...

Quick Take Nkarta ( NKTX ) intends to raise $150 million in an IPO of its common stock, according to an amended registration statement . The company is advancing a pipeline of drug candidates for the treatment of blood and other cancer indications. NKTX is still at preclinical stage of ...